Innovative formulation technology protecting intended drug action

Drug Development and Delivery

Volumn 12, Issue 8, 2012, Pages

  Bartholomäus, Johannes ^a   Ashworth, Judy B ^b   Stahlberg, Hans Jürgen ^b   Galia, Eric ^b   Strothmann, Kai ^b  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; OPIATE; PRESCRIPTION DRUG;

ARTICLE; DRUG ABUSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ABUSE; OPIATE ADDICTION; PRESCRIPTION; TABLET FORMULATION; UNITED STATES;

EID: 84867767021     PISSN: 15372898     EISSN: 1944818X     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (10)

1. http://www.cdc.gov/mmwr
2. http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf
3. Bartholomaeus JH, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opinion on Drug Delivery. 2012;9(8):879-891.
4. Stahlberg H, Brett M, Galia E, Ossig J, Wenge B. Bridging from conventional marketed extended release formulations to new tamper resistant alternatives. Journal Pain. 2012;13(4S):73.
5. Ashworth JB, Kowalczyk WJ, Stephens SL, et al. Effect of tablet mechanical stability on drug preference and relative street value of oxycodone controlled-release (CR) tablets in experienced oxycodone CR abusers. Paper presented at the 69th Annual Meeting of the College on Problems of Drug Dependence on June 16-21, 2007 in Quebec City, QC, Canada.
6. Sokolowska M, Comer SD, Sullivan MA, Ashworth JB. Can increasing mechanical stability of controlled release tablets decrease drug preference and the street value of the drug? [Abstract PM 387]. Paper presented at the 13th Congress of the International Association for the Study of Pain on August 29-September 2, 2010 in Montreal, QC, Canada. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=61f3d88d-52e8-404a-8e7a-ef29e654ada1&cKey=76cd0256-aba8-467c-a7ec-6b1d02acec8a&mKey=%7B3F846F23-E219-40A0-B790-DBC3F75684FD%7D
7. Vosburg SK, Jones JD, Manubay JM, et al. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend 2012; in press.
8. Black R, Coplan P, Cassidy T, et al. Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network. J Pain. 2012;13:S58.
9. Rappaport B. Deterrence of Prescription Opioid Abuse: FDA Perspective. FDA;2009.
10. Mitchell JF. Oral dosage forms that should not be crushed. 2011. Available from:http://www.ismp.org/tools/donotcrush.pdf